Highest-materiality recent filing
Perspective Therapeutics updates ASCO 2026 data; VMT-α-NET shows deepening responses in NETs
VMT-α-NET (212Pb for SSTR2+ NETs) shows best response deepens over time; durable disease control across doses; stable renal function in 68 patients.
VMT-α-NET (SSTR2+ NET) Phase 1/2a shows durable disease control; potential registration study at current dose level.
VMT01 in melanoma: 2/7 confirmed responses (29%) at 3.0 mCi; 6/7 stable disease or partial response.
Perspective Therapeutics updates VMT-α-NET Ph1/2a data and preliminary cash position
Preliminary cash & short-term investments as of Mar 31, 2026 disclosed; unaudited, subject to final adjustments.
Perspective reports 43% ORR, clean safety for [212Pb]VMT-α-NET in Phase 1/2a at AACR 2026
Objective response rate 43% (10/23) in Cohort 2 first half; 9 patients with deepening response since ESMO 2025.
Net loss $103.1M ($1.40/sh) vs $79.3M ($1.23) in FY2024; R&D spend $84.2M (+102% YoY).
Gross proceeds ~$175M from 39,576,088 shares at $3.79/share and 6,598,046 pre-funded warrants at $3.789.
Updated interim data from Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-expressing NETs at ASCO-GI.
Perspective Therapeutics reports 44% ORR in [212Pb]VMT-α-NET trial; cash $174.1M
Phase 1/2a data: 44% objective response rate (7/16) in Cohort 2 patients with SSTR2+ all tumors at median 41-week follow-up.
Perspective Therapeutics appoints Joel Sendek as CFO, replacing Juan Graham
Effective Sept 4, 2025; Sendek brings over 30 years of biotech finance and equity research experience.
Perspective Therapeutics Q2 net loss $21.5M, EPS -$0.29; cash $192M; VMT-α-NET Cohort 3 opened
Net loss of $21.5M ($0.29 per share) vs $11.7M ($0.18) in Q2 2024; operating expenses rose 65%.
FDA opened Cohort 3 at 6 mCi (20% higher than Cohort 2) per dose for patients weighing >60 kg.
Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET in NETs at ASCO 2025
No dose-limiting toxicities, no discontinuations due to AEs, and no Grade 4/5 TEAEs in 42 treated patients.
Perspective Therapeutics Q1 net loss $18.2M; VMT-α-NET cohort enrollment reaches 40 patients
Net loss $18.2M ($0.25 loss per share) vs $12.3M loss in prior year; R&D spend +92% to $14.3M.
Net loss of $79.3M ($1.23 loss per share) vs $46.5M in FY2023; R&D spend doubled to $41.6M.
Perspective Therapeutics doses first patient in [212Pb]VMT01 plus nivolumab combo cohort
First patient dosed with [212Pb]VMT01 at 1.5 mCi in combination with nivolumab (Opdivo) for MC1R+ metastatic melanoma Phase 1/2a trial.
Three objective responses (1 confirmed, 2 unconfirmed) in Cohort 2 at 5.0 mCi dose; 5 stable disease; 1 progressive disease.
Perspective Therapeutics reports $227.8M cash, updates on VMT-α-NET and VMT01 trials
Preliminary unaudited cash, equivalents and ST investments: $227.8M as of Dec 31, 2024, funding operations into late 2026.
No dose-limiting toxicities observed at 2.5 and 5.0 mCi doses; safety profile favorable.
Perspective Therapeutics Q3 net loss $15.1M ($0.21/share); cash $267.8M funds into mid-2026
Net loss from continuing and discontinued ops $15.1M vs $10.4M YoY; basic loss per share $0.21.
No dose-limiting toxicities; TEAEs mostly Grades 1–2; no renal toxicities reported despite high renal dosimetry.
Perspective Therapeutics enters €49M equipment deal with Comecer for radiopharmaceutical production
Agreement with Comecer SpA for manufacturing equipment including isotope processing hot cells and production suites.
FDA grants Fast Track Designation for Perspective's VMT01 in MC1R-positive melanoma
Fast Track for 212Pb VMT01: diagnosis and treatment of unresectable or metastatic MC1R-positive melanoma.
As of the Effective Date, Mr. Jonathan Hunt will no longer serve as the Company’s Chief Financial Officer but will remain in his role as the Company’s Chief Accounting Officer and principal accounting officer.
On January 2, 2025, the Board of Directors (the “Board”) of Perspective Therapeutics, Inc. (the “Company”) appointed Mr. Juan Graham as the Company’s Chief Financial Officer and principal financial officer, in each case effective as of January 6, 2025
Mark Austin ceased serving as an executive officer of the Company and as the Company's “co-principal financial officer” and “principal accounting officer” on August 16, 2024.
Effective as of the Effective Date, Jonathan Hunt, the Company’s Chief Financial Officer and “co-principal financial officer,” began serving as the Company’s sole “principal financial officer” and “principal accounting officer.”
On August 16, 2024 (the “ Effective Date ”), Mark Austin, the Vice President of Finance, Corporate Controller and Corporate Secretary of Perspective Therapeutics, Inc. (the “ Company ”), ceased serving as an executive officer and as the Company’s “co-principal financial officer” and “principal accounting officer.”
On July 10, 2023, Perspective Therapeutics, Inc. (the “Company”) terminated the employment of Jennifer Streeter, the Company’s Chief Operating Officer and Vice President of Human Resources, effective immediately.
Following Mr. McCormick’s resignation, effective as of June 1, 2023, the Board appointed Ms. Heidi Henson as a director of the Company to fill the vacant position on the Board and a member of the Audit (as Chairperson) and Compensation committees of the Board.
On May 9, 2023, Michael McCormick gave notice of his resignation from the Board of Directors of the Company (the “ Board ”), effective immediately.
In connection with the termination of William Cavanagh III from his position of Chief Research and Development Officer of Perspective Therapeutics, Inc. (the “ Company ”), as previously disclosed on the Form 8-K filed by the Company on February 10, 2023, the Company, Isoray Medical, Inc. (a wholly-owned subsidiary of the Company), and Mr. Cavanagh entered into a Separation Agreement effective March 10, 2023.
William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.
(iv) Dr. Frank Morich as a director of the Company
Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.
Max materiality 0.85 · Median 0.55 · Most common event other_material